Sevoflurane inhibits proliferation, induces apoptosis, and blocks cell cycle progression of lung carcinoma cells

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 12, 2011, Pages 3415-3420

  Liang, Hua ^a,b   Gu, Miao Ning ^a   Yang, Cheng Xiang ^b   Wang, Han Bing ^b   Wen, Xian Jie ^b   Zhou, Qiao Ling ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Lung cancer cells; Proliferation; Sevoflurane

Indexed keywords

ANTITHROMBOCYTIC AGENT; ETHER DERIVATIVE; SEVOFLURANE; TUMOR MARKER;

ADENOCARCINOMA; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CLONOGENIC ASSAY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; METHYL ETHERS; PLATELET AGGREGATION INHIBITORS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84864506684     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Altieri DC (2003). Survivin and apoptosis control. Adv Cancer Res, 88, 31-52.
2. Biki B, Mascha E, Moriarty DC, et al (2008). Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology, 109, 180-7.
3. Coffey JC, Wang JH, Smith MJ, et al (2003). Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol, 4, 760-8.
4. De Falco M, De Luca A (2010). Cell cycle as a target of antineoplastic drugs. Curr Pharm Des, 16, 1417-26.
5. Dean EJ, Ward T, Pinilla C, et al (2010). A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. Br J Cancer, 102, 97-103
6. Dong Y, Zhang G, Zhang B, et al (2009). The common inhalational anesthetic sevoflurane induces apoptosis and increases beta-amyloid protein levels. Arch Neurol, 66, 620-31.
7. de Oliveira GS Jr, Ahmad S, Schink JC, et al (2011). Intraoperative neuraxial anesthesia but not postoperative neuraxial analgesia is associated with increased relapse-free survival in ovarian cancer patients after primary cytoreductive surgery. Reg Anesth Pain Med, 36, 271-7.
8. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI (2006). Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology, 105, 660-4.
9. Hartwell LH, Kastan MB (1994). Cell cycle control and cancer. Science, 266, 1821-8.
10. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
11. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
12. Kvolik S, Glavas-Obrovac L, Bares V, Karner I (2005). Effects of inhalation anesthetics halothane, sevoflurane, and isoflurane on human cell lines. Life Sci, 77, 2369-83.
13. Kvolik S, Dobrosevic B, Marczi S, Prlic L, Glavas-Obrovac L (2009). Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand, 53, 1192-9.
14. Leber B, Geng F, Kale J, Andrews DW (2010). Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Rev Mol Med, 12, e28.
15. Li F (2005). Role of survivin and its splice variants in tumorigenesis. Br J Cancer, 92, 212-6.
16. Llambi F, Green DR (2011). Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev, 21, 12-20.
17. Lockshin RA, Zakeri Z (2001). Programmed cell death and apoptosis: origins of the theory. Nat Rev Mol Cell Biol, 2, 545-50.
18. Loop T, Scheiermann P, Doviakue D, et al (2004). Sevoflurane inhibits phorbol-myristate-acetate-induced activator protein-1 activation in human T lymphocytes in vitro: potential role of the p38-stress kinase pathway. Anesthesiology, 101, 710-21.
19. Merritt RE, Mathisen DJ, Wain JC, et al (2009). Long-term results of sleeve lobectomy in the management of non-small cell lung carcinoma and low-grade neoplasms. Ann Thorac Surg, 88, 1574-81.
20. Nigg EA (1995). Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays, 17, 471-80.
21. Oost TK, Sun C, Armstrong RC, et al (2004). Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem, 47, 4417-26.
22. Roesslein M, Frick M, Auwaerter V, et al (2008). Sevoflurane-mediated activation of p38-mitogen-activated stressskinase is independent of apoptosis in Jurkat T-cells. Anesth Analg, 106, 1150-60.
23. Rödel F, Hoffmann J, Distel L, et al (2005). Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res, 65, 4881-7.
24. Santamaria LB, Schifilliti D, La Torre D, Fodale V (2010). Drugs of anaesthesia and cancer. Surg Oncol, 19, 63-81.
25. Sessler DI (2009). Long-term consequences of anesthetic management. Anesthesiology, 111, 1-4.
26. Snyder GL, Greenberg S (2010). Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth, 105, 106-15.
27. Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S (2000). Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg, 232, 58-65.
28. Yildizeli B, Fadel E, Mussot S, et al (2007). Morbidity, mortality, and long-term survival after sleeve lobectomy for non-small cell lung cancer. Eur J Cardiothorac Surg, 31, 95-102.
29. Zheng M, Yang J, Xu X, et al (2010). Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide. Anticancer Res, 30, 3321-31.